利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

198 条记录 (耗时 0.04 秒)

    Mixing tool
    1.
    发明授权
    Mixing tool 失效
    混合工具

    公开(公告)号：US08147477B2

    公开(公告)日：2012-04-03

    申请号：US12597352

    申请日：2008-04-25

    申请人： Christine Smith ,  Rey Halili ,  Hong Qi

    发明人： Christine Smith ,  Rey Halili ,  Hong Qi

    IPC分类号： A61M5/32

    CPC分类号： A61J1/2096 ,  A61J1/201 ,  A61M5/002

    摘要： The present invention provides devices and methods for mixing a formulation containing two or more constituents, such as a drug product and a diluent. The devices have a chamber for securing a container of the drug product. Various embodiments are presented. In one embodiment the device has two or more sides connected by a hinge, the two or more sides defining the chamber between them, and a handle for grasping and manipulating the device. In another embodiment the device has a housing with two or more side bars defining the chamber, the container being visible from outside the housing between the side bars and having a stopping element at the distal end, and a handle having two arms for grasping.

    摘要翻译： 本发明提供了用于混合含有两种或更多种成分（例如药物产品和稀释剂）的制剂的装置和方法。 这些装置具有用于固定药物产品的容器的腔室。 呈现各种实施例。 在一个实施例中，该装置具有通过铰链连接的两个或多个侧面，两个或多个侧面在它们之间限定室，以及用于抓握和操纵该装置的手柄。 在另一个实施例中，该装置具有壳体，其具有限定腔室的两个或多个侧杆，容器从侧杆之间的壳体外部可见，并且在远端具有止动元件，以及具有用于抓握的两个臂的手柄。

    EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES
    3.
    发明申请
    EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES 审中-公开
    降低胆固醇和胆固醇

    公开(公告)号：US20110263496A1

    公开(公告)日：2011-10-27

    申请号：US12992060

    申请日：2009-05-20

    申请人： Mark Fineman ,  Leigh MacConell ,  Kristin Taylor

    发明人： Mark Fineman ,  Leigh MacConell ,  Kristin Taylor

    IPC分类号： A61K38/26 ,  A61P9/10 ,  A61P3/06

    CPC分类号： A61K38/179 ,  A61K9/5031 ,  A61K38/2278 ,  A61K38/26 ,  A61K47/34

    摘要： Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

    摘要翻译： 本文提供含有以持续时间段以治疗血浆浓度水平施用以降低总胆固醇水平的毒蜥吐宁，毒蜥外泌肽激动剂或毒蜥外泌肽类似物激动剂的药物制剂; 降低低密度脂蛋白胆固醇水平; 降低甘油三酯水平; 治疗血脂异常 治疗和减缓动脉粥样硬化的进展; 并治疗，预防和减少患者心脏病发作和中风的风险。 在本发明的药物制剂和方法中，毒蜥外泌肽可以是毒蜥外泌肽-4，毒蜥外泌肽-4激动剂或毒蜥外泌肽-4类似物激动剂。 药物制剂可以是可以每周一次施用的基于聚合物的药物制剂。 示例性药物制剂包含5％（w / w）的艾塞那肽，约2％（w / w）的蔗糖和约93％（w / w）的聚（丙交酯 - 共 - 乙交酯）聚合物，其中聚 （丙交酯 - 共 - 乙交酯）聚合物是包封艾塞那肽的微胶囊形式。

    Methods of treatment using exendin peptides or GLP-1 peptides
    5.
    发明授权
    Methods of treatment using exendin peptides or GLP-1 peptides 有权
    使用毒蜥外泌肽或GLP-1肽的治疗方法

    公开(公告)号：US07928065B2

    公开(公告)日：2011-04-19

    申请号：US12247141

    申请日：2008-10-07

    申请人： Andrew A. Young ,  Will Vine ,  Nigel R. A. Beeley ,  Kathryn S. Prickett

    发明人： Andrew A. Young ,  Will Vine ,  Nigel R. A. Beeley ,  Kathryn S. Prickett

    IPC分类号： A61K38/22 ,  C07K14/575

    CPC分类号： A61K38/26 ,  A61K31/00 ,  A61K38/2278 ,  Y10S514/866

    摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

    摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。

    Treatment of cardiac arrhythmias with GLP-1 receptor ligands
    6.
    发明授权
    Treatment of cardiac arrhythmias with GLP-1 receptor ligands 有权
    用GLP-1受体配体治疗心律失常

    公开(公告)号：US07790681B2

    公开(公告)日：2010-09-07

    申请号：US10740146

    申请日：2003-12-17

    申请人： David R. Hathaway ,  Alain D. Baron

    发明人： David R. Hathaway ,  Alain D. Baron

    IPC分类号： A61K38/16 ,  A61K38/28

    CPC分类号： A61K38/26 ,  A61K31/7004 ,  A61K33/00 ,  A61K38/2278

    摘要： Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.

    摘要翻译： 本发明的组合物，包括与胰高血糖素样肽-1的受体结合的化合物，肠降血糖素，胰高血糖素样肽-1（GLP-1），毒蜥外泌肽或激动剂，类似物（优选激动剂 类似物），任何前述化合物的衍生物或变体，用于预防和治疗与心脏缺血，心脏缺血灌注和/或充血性心力衰竭相关的心律失常。 本发明涉及这种治疗的方法和组合物。

    Native chemical ligation with three or more components
    9.
    发明授权
    Native chemical ligation with three or more components 失效
    天然化学结合三个或更多成分

    公开(公告)号：US07662914B2

    公开(公告)日：2010-02-16

    申请号：US10476447

    申请日：2002-05-31

    申请人： Matteo Villain ,  Hubert Gaertner

    发明人： Matteo Villain ,  Hubert Gaertner

    IPC分类号： A61K38/00

    CPC分类号： C07K1/026 ,  Y02P20/55

    摘要： The invention provides a method of assembling oligopeptide intermediates in a native chemical ligation reaction that eliminates self-ligation of bi-functional intermediates. An important aspect of the invention is a bi-functional intermediate with an N-terminal cyclic thiazolidine protecting group which effectively prevents self-ligation in the chemical assembly process. The present invention is useful in methods for convergent synthesis of polypeptides and proteins and improves the efficiency of native chemical ligation reactions, particularly where three or more peptide fragments are used to assemble a polypeptide or protein product.

    摘要翻译： 本发明提供了在天然化学连接反应中组装寡肽中间体的方法，其消除双功能中间体的自连接。 本发明的一个重要方面是具有N-末端环状噻唑烷保护基的双功能中间体，其有效地防止化学组装过程中的自连接。 本发明可用于多肽和蛋白质的收敛合成的方法，并提高天然化学连接反应的效率，特别是在使用三个或更多个肽片段来组装多肽或蛋白质产物的情况下。